Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

• DOI: 10.1016/j.annonc.2024.06.009
• Publication Date: 2024-06-20T07:15:34Z
• Authors: L. Arecco; M. Bruzzone; R. Bas; H.J. Kim; A. Di Meglio; R. Bernstein-Molho; F.S. Hilbers; K. Pogoda; E. Carrasco; K. Punie; J. Bajpai; E. Agostinetto; N. Lopetegui-Lia; A.H. Partridge; K.A. Phillips; A. Toss; C. Rousset-Jablonski; G. Curigliano; T. Renaud; A. Ferrari; S. Paluch-Shimon; R. Fruscio; W. Cui; S.M. Wong; C. Vernieri; F.J. Couch; M.V. Dieci; A. Matikas; M. Rozenblit; D. Aguilar-y Méndez; L. De Marchis; F. Puglisi; A. Fabi; S.L. Graff; I. Witzel; A. Rodriguez Hern...; A. Fontana; R. Pesce; R. Duchnowska; H.L. Pais; V. Sini; E. Sokolović; E. de Azambuja; M. Ceppi; E. Blondeaux; M. Lambertini
• Keywords: Adult; BRCA2 Protein; Heterozygote; BRCA1 Protein; Receptor, ErbB-2; 610; Breast Neoplasms; Prognosis; Disease-Free Survival; Young Adult; Receptors, Estrogen; BRCA; early breast cancer; hormone receptor status; tumor subtypes; young patients; Biomarkers, Tumor; Humans; Female; Receptors, Progesterone; Germ-Line Mutation; BRCA; early breast cancer; hormone receptor status; tumor subtypes; young patients;; Retrospective Studies

Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its impact prognosis of young patients harboring pathogenic variant (PV) the BRCA1 and/or BRCA2 genes.